Meeting Banner
Abstract #0732

1 H MRS Monitoring of GABAergic and Glutamatergic Response to 4 Weeks of Antipsychotic Treatment in Medication-nave First-episode Psychosis Patients

Camilo de la Fuente-Sandoval 1 , Francisco Reyes-Madrigal 2 , Xiangling Mao 3 , Pablo Len-Ortiz 4 , Oscar Rodrguez-Mayoral 5 , Helgi Jung-Cook 6 , Ariel Graff-Guerrero 7 , Rodolfo Solis-Vivanco 8 , and Dikoma C Shungu 3

1 Neuropsychiatry & Laboratory of Experiment Psychiatry, Instituto Nacional de Neurologa y Neurociruga (INNN), Mexico City, Distrito Federal, Mexico, 2 Laboratory of Experimental Psychiatry, INNN, Mexico City, Mexico, 3 Radiology, Weill Cornell Medical College, New York, NY, United States, 4 Education, INNN, Mexico City, Mexico, 5 Palliative Care Unit, Instituto Nacional de Cancerologa, Mexico City, Mexico, 6 Laboratory of Neuropsychopharmacology, INNN, Mexico City, Mexico, 7 Multimodal Neuroimaging Schizophrenia Group, Centre for Addiction and Mental Health, Toronto, ON, Canada, 8 Laboratory of Neuropsychology, INNN, Mexico City, Mexico

Dysregulations of GABA and glutamate are implicated in schizophrenia pathophysiology. Using 1 H MRS, GABA and glutamate+glutamine (Glx) levels were measured at baseline and after 4 weeks of antipsychotic treatment in the medial prefrontal cortex (MPFC) and dorsal caudate (DCA) of medication-naive first-episode psychosis (FEP) patients and matched health controls. The results showed higher baseline levels of both GABA and Glx in the MPFC and DCA of FEP subjects than in controls, which normalized in both brain regions after 4 weeks of treatment. These data suggest that schizophrenia is characterized by elevations of GABA and Glx, which normalize with antipsychotic treatment.

This abstract and the presentation materials are available to members only; a login is required.

Join Here